AF
TRML

Amalgamated Financial’s Tourmaline Bio TRML Stock Holding History

Amalgamated Financial’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$31K Buy
+318
New +$29.8K ﹤0.01% 2610

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Amalgamated Financial's TRML Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Tourmaline Bio (TRML) in Q1 2022: 318 shares worth $31K. The stake represents ﹤0.01% of the portfolio and ranks #2610 among its holdings.

51 funds tracked by Wall St. Rank hold TRML as of Q1 2022.

  • Amalgamated Financial held 318 shares of Tourmaline Bio worth $31K as of Q1 2022.
  • Tourmaline Bio was a new Amalgamated Financial position in Q1 2022.
  • Tourmaline Bio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2610 holding.
  • 51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.